Washington, DC (January 27, 2024) — UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement in response to the U.S. Food and Drug Administration’s (FDA) approval of the once every four-week maintenance dosing of Leqembi for the treatment of early Alzheimer’s disease:

“The approval of once every four-week maintenance dosing of Leqembi is an important step forward in improving the care and quality of life for people living with early Alzheimer’s disease, as well as their caregivers.

“For families facing the challenges of Alzheimer’s care, every improvement in convenience and treatment advancement matters. Frequent visits to the clinic or treatment center can be burdensome, and the once every four-week dosing regimen allows a much-needed reduction in that strain, making it easier for families to stay on track with treatment and extend the benefits of therapy.

“We are hopeful that this milestone will drive further innovation and increase access to treatments that ease the burden on both patients and their caregivers facing this devastating disease.”

About UsAgainstAlzheimer’s
UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.